Which class of drugs does Axitinib belong to and what exactly does it do?

Axitinib (Axitinib) is a targeted anti-cancer drug that belongs to the class of small molecule tyrosine kinase inhibitors (TKI). It is mainly used to treat advanced renal cell carcinoma (RCC). It selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR) 1, 2 and 3, thereby blocking the angiogenesis process of tumors and inhibiting the nutrient supply and growth and spread of tumors. Since angiogenesis plays a key role in tumor development, axitinib effectively inhibits tumor development through this mechanism.

In clinical application, axitinib is widely used in patients with advanced renal cancer who have progressed after previously receiving a systemic therapy (such as sorafenib). Multiple clinical studies have confirmed that axitinib can significantly prolong progression-free survival (PFS), and some patients even experienced good responses to tumor shrinkage or control. As a second-line treatment drug, axitinib has a clear mechanism of action and may also be effective in some patients who are resistant to other VEGFR-TKIs.

In addition to renal cell carcinoma, some studies are also exploring the potential application of axitinib in other solid tumors (such as thyroid cancer, lung cancer), but these uses have not yet been widely approved and are still in the clinical research stage. Due to its high selectivity, axitinib has relatively little impact on normal cells, and some patients can maintain a stable disease state for a longer period of time during use.

Overall, axitinib is a targeted drug targeting tumor angiogenesis with stable efficacy and clear mechanism of action. It is one of the important choices in the treatment of advanced renal cancer. During use, it is necessary to closely monitor blood pressure, liver and kidney function and other indicators, and pay attention to common side effects such as high blood pressure, diarrhea, fatigue, etc., so that timely treatment and dose adjustment can be made.

Reference materials:https://en.wikipedia.org/wiki/Axitinib